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his latest edition of Neurotransmitter represents another step forward in our effort to 
communicate the progress taking place among the clinical partners at the George 
Washington University (GW). Inside these pages, we illuminate the rich tapestry of 
the neurosciences and the broad expertise of the GW Institute for Neuroscience 
(GWIN) and the GW University Hospital Neurological Institute.
This third magazine deals with subjects that overwhelm daily headlines. Doug-
las Nixon, M.D., Ph.D., chair of the Department of Microbiology, Immunology, and 
Tropical Medicine and Walter G. Ross Professor of Basic Science Research at GW’s 
School of Medicine and Health Sciences (SMHS), leads a group of investigators from 
across the University who are exploring how the Zika virus may produce devastat-
ing abnormalities in brain development and identifying other likely areas of ner-
vous system infection. Neurotransmitter also discusses the psychiatric ramifications 
of the global refugee crisis.
We are excited to announce a major recruitment to GW. Kevin Pelphrey, Ph.D., a 
world-renowned investigator on autism, will lead the GW Autism and Neurodevel-
opmental Disorders Institute. Pelphery will build collaborations across several GW 
colleges, including SMHS, the Columbian College of Arts and Sciences, and the 
Milken Institute School of Public Health, as well as with clinical partners the GW Hos-
pital, the GW Medical Faculty Associates, and Children’s National Health System. 
Collaborations are key to excellence in science and medicine. The Joint Com-
mission recently acknowledged our collective efforts by designating GW Hospital 
as a comprehensive stroke center. The commission noted how well the GW Hospital 
administration, staff, and physicians worked together to provide advanced stroke 
care. We offer a personal account of the impact modern stroke care has had on 
one of our patients. In addition to this success story, we provide an update on the 
groundbreaking research of Mohamad Koubeissi, M.D., and Donald Shields, M.D., 
Ph.D., FACS, in dramatically reducing the frequency of seizures among patients with 
epilepsy. 
Beyond the research conducted at GW, we feature pieces on scientists who 
visited us to present their work. At GWIN’s 6th Annual Neuroscience Symposium, 
investigators from across the country presented discoveries in multiple sclerosis 
and Alzheimer’s disease. GW also welcomed back former psychiatry resident Bran-
don Kohrt, M.D., Ph.D., RESD ’13, who gave the prestigious Seymour Perlin, M.D., 
lecture. 
We hope you enjoy this edition of Neurotransmitter.
Please go to smhs.gwu.edu/neurotransmitter to view or share a copy of this or 
previous editions of Neurotransmitter.
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THE NEURO-IMMUNE INTERFACE:  
GLIA, NEURONS, AND DISEASE 
Neuro-immune diseases — particularly Alzheimer’s, multiple sclerosis (MS), and myas-
thenia gravis (MG) — took center stage at the 6th Annual Neuroscience Symposium, a 
day-long event sponsored by the GW Institute for Neuroscience. “The Neuro-Immune 
Interface: Glia, Neurons, and Disease”-themed symposium featured two keynote speak-
ers, as well as presenters from the GW School of Medicine and Health Sciences (SMHS) 
and Children’s National Health System (Children’s National).
“This [symposium] is a wonderful thing to do,” said keynote speaker Carla Shatz, 
Ph.D., Sapp Family Provostial Professor, David Starr Jordan Director of Stanford Bio-X, 
and professor of biology and neurobiology at Stanford University. 
Shatz, in “Saving the Synapse: Developmental Critical Periods and Alzheimer’s Dis-
ease,” asserted that if researchers could better understand the cellular and molecu-
lar mechanisms underlying developmentally critical periods, then they could use the 
mechanisms in the adult brain to help repair injuries in stroke and Alzheimer’s patients. 
The second keynote speaker, Stephen L. Hauser, M.D., Robert A. Fishman Distin-
guished Professor and chair of the Department of Neurology at the University of Cali-
fornia – San Francisco, focused on MS.
Hauser, whose research targeted B cell-based therapies and their impact on the dis-
ease, found that antibodies targeting cells that promote antibody production reduced 
disease activity within weeks of treatment. “This discovery … enabled a paradigm shift 
in understanding how the inflammatory phase of MS develops,” he said.
Robert Miller, Ph.D., senior associate dean for research and Vivian Gill Distinguished 
Research Professor at SMHS, who presented “Cellular Interactions Regulating CNS My-
elination, Demyelination, and Early Myelin Repair in Vertebrate CNS,” also focused on 
MS, namely the role of astrocytes, or star-shaped glial cells in the brain and spinal cord, 
in myelination, the creation of the fatty insulation protecting nerves.
In addition to the research on Alzheimer’s and MS, Linda Kusner, Ph.D., associate re-
search professor of pharmacology and physiology at SMHS, discussed MG, a rare and 
debilitating autoimmune disorder that causes muscle weakness. Through her work, 
Kusner discovered that the expression of the protein survivin could be part of a mecha-
nism that keeps cancer cells alive, thereby linking cancer and autoimmune disease in 
MG and other autoimmune disorders.
This year’s symposium also included discussions from SMHS Ph.D. candidates and 
postdoctoral fellows as well as poster presentations from SMHS and Children’s Na-
tional researchers.
STEPHEN L. HAUSER, M.D. LINDA KUSNER, Ph.D. CARLA SHATZ, Ph.D. 
Stephen Hauser, 
M.D., found in 
his research that 
antibodies targeting 
cells that promote 
antibody production 
reduced disease 
activity within weeks 
of treatment. “This 
discovery … enabled 
a paradigm shift in 
understanding how 
the inflammatory 
phase of MS 
develops.”
Through her research, Linda Kusner, Ph.D., discovered that the expression of the protein 
survivin keeps cancer cells alive, thereby linking cancer and autoimmune disease.
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SPANNING THE SPECTRUM OF AUTISM
The George Washington University’s research portfolio has recently begun to expand 
thanks to the expertise of Kevin Pelphrey, Ph.D., new director of the Autism and Neuro-
developmental Disorders Institute (ANDI) and professor of pharmacology and physiol-
ogy at the GW School of Medicine and Health Sciences.
Pelphrey will connect the University’s full research spectrum, including faculty mem-
bers representing six GW colleges, with clinical partners GW Hospital, Children’s Na-
tional Health System, and the GW Medical Faculty Associates. The goal is to create a one-
stop resource for families affected by autism in the Washington, D.C. metropolitan area.
Pelphrey, who is the parent of a child with autism, has more than 15 years of experi-
ence in autism and neuroscience research. He specializes in cognitive neuroscience 
and developmental disorders and currently holds seven active grants, including a $15 
million National Institutes of Health grant from the Autism Centers of Excellence Pro-
gram. Pelphrey will also be the first to hold the endowed title of the Carbonell Family 
Professor in Autism and Neurodevelopment Disorders.
At ANDI, which received $5 million from GW and will be located on the University’s 
Virginia Science and Technology Campus in Ashburn, Virginia, Pelphrey and his team 
will focus on adults with autism and women with autism.
TAKING AIM AT NEW TARGETS FOR 
MYASTHENIA GRAVIS TREATMENT
Linda Kusner, Ph.D., associate research pro-
fessor in the department of pharmacology 
and physiology at the GW School of Medicine 
and Health Sciences, received a multi-year 
Muscular Dystrophy Association research 
grant totaling nearly $300,000 to provide a 
new fundamental understanding of the basic 
mechanisms of autoimmunity and validating a 
new therapeutic target for myasthenia gravis 
(MG).
Kusner aims to develop a therapy for MG 
that might eliminate or lessen the need for 
corticosteroids, the current standard of care. 
With colleagues, she has discovered a pro-
tein called survivin present in MG-affected 
cells that the group believes supports the 
presence of autoreactive immune cells by al-
lowing them to escape cell death. In studies 
that targeted the protein, Kusner and her team observed a reduction in the 
levels of antibodies in the MG disease process.
In her new work, Kusner will analyze thymus tissue from MG patients as well 
as from healthy individuals to determine whether the survivin protein is pres-
ent in both instances. Kusner’s team also will evaluate survivin-based thera-
peutics in an MG rodent model to assess the therapeutics’ ability to improve 
observable weakness, decrease the expression of autoreactive immune cells, 
decrease acetylcholine receptor-specific antibodies, and decrease damage 
to the nerve-muscle junction.
KEVIN PELPHREY, Ph.D.
Director of the Autism 
and Neurodevelopmental 
Disorders Institute and 
professor of pharmacology 
and physiology at the 




Henry Kaminski, M.D., chair of the De-
partment of Neurology and Meta Ama-
lia Neumann Professor of Neurology at 
the GW School of Medicine and Health 
Sciences, has found that removing the 
thymus effectively reduced patients’ 
muscle weakness, as well as the need 
for immunosuppressive drugs and hos-
pitalizations.
“While surgery is expensive and not 
without risk, this research will empow-
er patients and their doctors to make 
informed decisions regarding treat-
ment,” said Kaminski.
Previous studies have suggested 
that removing the thymus may re-
duce MG symptoms — droopy eyelids; 
blurred or doubled vision; difficulty 
talking, breathing, and swallowing; 
and neck and limb movement prob-
lems — but Kaminksi’s study, published 
in the New England Journal of Medi-
cine, is the first randomized study of 
thymectomy in MG patients, providing 
clinical evidence of the benefits of the 
surgery.
IN MYASTHENIA GRAVIS 
the immune system makes 
antibodies that damage or 
block many of the muscle’s 
acetylcholine receptors on 
the surface of muscle cells, 
preventing the chemical from 
binding to the damaged 
receptors and reducing 
muscle contractions, leading 
to weakness and fatigue. 
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Beyond the Buzz 
GW RESEARCHERS JOIN INTERNATIONAL ACTION ON THE ZIKA VIRUS 
BY C.J. TRENT-GURBUZ
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he countdown at the University of Wiscon-
sin-Madison (UW) began on March 7, 2016, 
when researcher David O’Connor, Ph.D., 
professor in the Department of Pathology 
and Laboratory Medicine at the School of 
Medicine and Public Health at UW, and his 
team infected a pregnant rhesus macaque monkey with the 
Zika virus. 
“They’re releasing all of the results from her pregnancy, 
live,” says Chiara Manzini, Ph.D., assistant professor of phar-
macology and physiology at the GW School of Medicine and 
Health Sciences (SMHS). “They’re planning to do a C-section 
as soon as she’s ready because they want to get the placenta 
[to analyze it].”
The free flow of data from UW is standard — now — for Zika 
virus research. While in the past, investigators might have 
worked in siloed environments, the Zika virus has spurred re-
searchers around the globe to share data as soon as possible. 
“This is a race,” Manzini says.
In the months since the World Health Organization de-
clared the Zika virus an international public health emer-
gency, researchers have made significant strides; specifically, 
they’ve connected the virus to neurological disorders and 
established public health protocols for those living in, or visit-
ing, the Zika zone. 
“Research has not only 
added to the body of evidence 
suggesting that Zika virus does 
cause microcephaly, but there 
are also additional sugges-
tions that neurological dam-
age in infants born to mothers 
who have become infected 
with Zika during pregnancy is 
worse than we thought,” ex-
plains Douglas Nixon, M.D., 
Ph.D., chair of the Department 
of Microbiology, Immunology, and Tropical Medicine and 
Walter G. Ross Professor of Basic Science Research at SMHS. 
“There may be a number of different neurological problems 
in addition to microcephaly that infants may develop.”
Or, as Manzini phrases it: “Microcephaly is just the tip of 
the iceberg.”
The virus, she explains, infects the brain and kills the 
proliferating cells, which can cause severe growth defects 
in the developing fetal brain. Microcephaly, a condition 
in which a baby is born with an abnormally small head and 
potential brain damage, is one possible result, as is Guillain-
Barré Syndrome, a rare autoimmune disorder of the central 
nervous system.
It’s precisely because the virus has been linked to these 
disorders that researchers are sharing data as they sprint to-
ward a solution.
“Nobody has the general expertise to deal with this; it isn’t 
like other epidemics where it’s simply the passing of the virus 
and it just infects the host,” says Jeffrey Bethony, Ph.D., pro-
fessor of microbiology, immunology, and tropical medicine 
at SMHS. “[Zika] has long-term effects that you wouldn’t even 
know existed unless you had a multidisciplinary team.”
That team includes people like himself, a vaccinologist, 
and those such as Manzini, who studies brain malformations, 
as well as neurologists and fetal immunologists. For her part, 
Manzini is using a zebrafish model to look at “brain develop-
ment in real time on a very short timeline.” Researchers have 
also looked at other animal models — the rhesus macaque at 
UW, mice, and fruitflies — and while none are precisely perfect 
for Zika, all offer some type of information, Manzini says, add-
ing to the communal pool of data.
The National Institutes of Health (NIH) is also working to 
develop a vaccine as soon as possible, though that comes 
with certain challenges, according to Nixon and Bethony. 
The NIH has to ensure the vaccine isn’t more harmful than the 
virus; in other words, it has to be safe. It’s a process that re-
quires significant testing despite the urgency. 
“Who do you want to vaccinate?” Bethony asks. “You want to 
vaccinate women of childbearing years, or potential mothers.” 
Developing a vaccine for such a patient group is particu-
larly difficult, he says, adding “the idea of a physician is ‘do no 
harm,’ so they’re going to be very cautious.”
Right now, according to the NIH, its National Institute of 
Allergy and Infectious Diseases (NIAID) is focusing on a DNA-
based vaccine similar to the West Nile Virus vaccine. Research-
ers also are exploring a live-attenuated, or weakened, vaccine 
that’s related to the vaccine for dengue virus, which is a mem-
ber of the Flavivirus genus, like Zika, yellow fever, and chikun-
gunya. NIAID is looking at other potential vaccine approaches 
as well, including a whole-particle inactivated vaccine similar 
to that used against dengue and Japanese Encephalitis. 
“In terms of physically making a vaccine that could be tested 
in people, I think we’re getting close — quite soon,” says Nixon.
Meanwhile, at GW, those interested in Zika-related re-
search are applying for grants, and a Zika interest group, Nix-
on says, has formed between those at SMHS, the GW Milken 
Institute School of Public Health, and GW clinical partners, 
the GW Medical Faculty Associates and Children’s National 
Health System.
“People are becoming excited about Zika research,” he 
says, “and it really is a very exciting opportunity.”
T
MAKING STRIDES
In the months since the World 
Health Organization declared 
the Zika virus an international 
public health emergency, re-
searchers have connected the 
virus to neurological disorders 
and established public health 
protocols for those living in, 
or visiting, the Zika zone.
“Microcephaly is just the 
tip of the iceberg.”
 CHIARA MANZINI, Ph.D.
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GW RESEARCHER EXPLORES NEURAL DEVELOPMENT FROM ITS EARLIEST STAGE
BY THOMAS KOHOUT AND ERIC BUTTERMAN
ou see it all the time, couples placing headphones on a pregnant woman’s belly to share 
a little Bach or Beatles with their soon-to-be newborn, reading the stories they imagine 
one day telling just before bedtime, or stomaching all manner of juice concoctions in an 
effort to strike that ideal nutritional balance. It’s all done in the name of development. In 
the anxious months leading up to the birth of a child, expectant parents will try just about 
anything to give their growing baby a little edge. 
But what’s really going on during pregnancy? How 
aware is that fetus growing inside? What can science do 
to ensure the best possible outcome after birth? Despite 
all that medical professionals have come to know about 
pregnancy, neural development remains more enigmatic 
than indubitable. Unravelling the complex wiring process-
es taking place within the developing brain may allow for 
early recognition of neurological problems affecting life 
after birth.
With the support of a nearly $2 million grant in 2013 from the National Eye Institute, 
Matthew Colonnese, Ph.D., assistant professor of pharmacology and physiology at the 
GW School of Medicine and Health Sciences (SMHS) and a researcher with the George 
Washington University Institute for Neuroscience, is working to shed more light on the 
fetal brain developmental period in the hopes of providing those answers.
Eyeing Development
Colonnese has been exploring the subject of fetal brain development for years, dating 
back to his days as a graduate student. “At Yale, I was studying how the retina lines up to 
targets centrally. We knew this required activity in these targets, but had little idea what 
this activity consisted of.” Exploring how the brain constructs the neural circuitry that links 
the retina to the thalamus and the cerebral cortex, Colonnese says, ultimately led him to 
the work he delves in today.
Colonnese wanted to understand the timeline in brain development when the various 
pieces of the brain begin to talk to one another. Before arriving at GW, he collaborated 
with a team of clinicians in Paris who made brainwave recordings on preterm infants, at 
ages before they would have been born — in gestational weeks 28–34. The group also 
studied neural activity in the cortex using baby rats. 
“We designed an experiment to give those pre-term infants light flashes and did the 
same with the rats,” explains Colonnese, who heads SMHS’s Laboratory of Systems Neural 
Development. “We could map the activity patterns that were occurring in the babies onto 
the rat.”
The work established a baseline for comparison between the fetal rat brain and the hu-
man fetus. By matching brainwave patterns, and understanding what patterns to expect 
WHAT’S GOING ON?
Knowing how aware a fetus is 
in the womb may allow for rec-
ognition of problems with the 
fetus earlier, which, combined 
with treatment, might just alter 
quality of life concerning issues 
such as preterm infancy.
Y




in circuits are 
specialized, and it’s 
a specifically tuned 
system at work 
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at the equivalent ages, researchers could extrapolate ob-
servations in the rat and mouse models onto the fetal brain 
development timeline. 
Measuring the Flow
In his investigations, Colonnese has noted that many of the 
neural circuits in the fetal brain are specialized and specifi-
cally tuned to complete a developmental task that is differ-
ent than the task they perform in the adult brain. Colonnese 
wondered whether the specialized properties of the fetal 
neurocircuitry might prevent the normal flow of information 
from the eye to the brain. 
Using an array of electrodes to simultaneously record the 
activity of hundreds of neurons across multiple regions of 
the brain, the team discovered that the thalamus, acting as 
a way station for signals traveling between the eye and the 
cortex, contains a “booster” that amplifies the signals before 
sending them to the rest of the brain. Those observations 
were published in the October edition of eLife.
Typically in the adult brain, the eye sends information in 
a specific pattern, explains Colonnese. The eye transmits a 
refined stream of signals. “In the adult brain, it’s graded,” he 
says. “If you see a little bit of light, you get a little response; if 
you see a lot of light, you get a big response.”
In the fetal brain, on the other hand, the eye doesn’t pro-
vide that same pattern. Instead, the retina sends a massive 
burst of activity that Colonnese believes reflects a unique 
circuitry there to amplify the activity early in fetal develop-
ment. “In the fetal brain, you get nothing, nothing, nothing, 
BOOM! You get everything.
“You can’t see using that information,” he adds. “It’s a just 
massive burst of stuff that is going through telling the other 
parts of the brain, ‘yes something happened.’ ”
Colonnese believes this booster mechanism has evolved 
to help maintain signal strength between the various parts 
of the brain while the circuitry is being established. The am-
plifier, he says, explains how the fetal brain continues to stay 
active despite underdeveloped synapses.
The next goal, Colonnese says, will be to generate a kind 
of EEG “atlas” of neurodevelopment, pinpointing when the 
fetal brain transitions from a developmental stage to more 
adult-like patterns of behavior. With that information at their 
disposal, he says, physicians could identify problems with 
particular brain regions through disruptions in brain activity.
“This may give neonatologists a sense of what is wrong 
with a child who has an abnormal EEG,” he says, and point to 
a possible plan to address those problems.
The Search is Just Starting
Despite early strides, the major challenge will continue to 
be understanding the large number of changes during the 
brain’s development. Colonnese explains that trying to link 
a specific pattern change to a specific circuit can be similar 
to searching for a needle in a haystack.
“Everything is changing. How do you separate one 
change among the many we are observing?” he asks. “Our 
approach is to systematically go through the many potential 
candidate cells, neurotransmitters, and receptors and re-
move them, one by one, to see which can modify the timing 
of development.”
Colonnese knows there is a long way to go in his work, but 
the days with little to go on are worth it for the ones that re-
veal breakthroughs. “You think about the brainwave patterns 
in the fetus that have been described for something like 50 
years, but their origin has always been mysterious,” he says. 
“What’s most interesting to me are spending days sticking 
electrodes in and having no idea what you will see. It’s com-
pletely unknown — it feels like exploring the moon — and it’s 
even trying to answer the most basic question: ‘Why is the 
fetus kicking?’ You don’t have to be a researcher to ask that 
one. But hopefully this work will be a part of answering it.”
“What’s most interesting to me are spending days sticking electrodes in and having no 
idea what you will see. It’s completely unknown — it feels like exploring the moon.”
MATTHEW COLONNESE, Ph.D.
MATTHEW COLONNESE, Ph.D.
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TRACKING THE RESULTS OF LOW-FREQUENCY DEEP BRAIN STIMULATION ON EPILEPSY PATIENTS
BY C.J. TRENT-GURBUZ
hen the National Geographic 
cameras began rolling last year, 
Danette Cunningham was strug-
gling with epilepsy: she had 
twice suffered from seizures 
while driving and had experi-
enced constant shakiness. Cunningham’s sei-
zures originated from both hippocampi; 
for her, surgery would not be an op-
tion, and medications had already 
proven ineffective. Mohamad 
Koubeissi, M.D., director of the 
Epilepsy Center and associate 
professor of neurology at the 
GW School of Medicine and 
Health Sciences (SMHS), how-
ever, had a potential solution.
As documented in the 
TV show “Breakthroughs,” 
Koubeissi used a pio-
neering approach to treat 
Cunningham and a second patient, Yakov Krug, 
both of whom were diagnosed with temporal lobe epi-
lepsy. Koubeissi, and a GW Hospital surgical team led by 
Donald Shields, M.D., Ph.D., FACS, assistant professor of 
neurological surgery, implanted a permanent electrode 
for Deep Brain Stimulation 5 inches inside the brains of 
Cunningham and Krug. The stimulator sent out low fre-
quency electrical pulses into the hippocampus.
“All previous trials used high frequencies in the range 
of 90 to 130 pulses per second, or hertz; that’s very high,” 
Koubeissi explains. “In the current trial, what we’re using 
is 1 to 5 hertz, so it’s low frequencies, which explains why 
the patient doesn’t feel anything. Over time, 
this stimulation tends to alter the seizure 
network or create changes within the 
seizure network that paves the road 
to fewer seizures and maintains 
or even improves cognitive 
function.”
A month after healing, 
Cunningham and Krug each 
showed a massive reduction 
in their seizures. 
“In previous deep brain 
stimulation trials, the results 
have never been that good,” 
Koubeissi says. “There are 
numerous other targets in the 
brain that have been tried, and, 
in the best of subjects, seizures de-
crease by 30 percent or 40 percent, and 
some patients do not seem to benefit at all. 
Despite the small sample in our study, the benefit is 
more than 90 percent.”
A year has since passed, and the results, though lim-
ited to two patients, “continue to be unique and prom-
ise to be a real game changer.” The next step, Koubeissi 
says, is identifying more patients who fit the criteria for 
the procedure and designing an extensive clinical trial. 
He’d also like to apply for funding and, depending on 
the efficacy and tolerability of the intervention in a larger 
sample, seek FDA approval. 
Koubeissi is encouraging any patients who might qual-
ify for the treatment to reach out to the SMHS Department 
of Neurology’s research office at raly@mfa.gwu.edu.
W
The Stimulation Inspiration
“In previous deep brain 
stimulation trials, the results 
have never been that good.”
 MOHAMAD KOUBEISSI, M.D.
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GW HOSPITAL’S STROKE TEAM IS AMONG THE NATION’S LEADERS IN ACUTE CARE
BY STEVE GOLDSTEIN
ast autumn, an ambulance rushed into the emergency entrance of George Washington 
University Hospital (GW Hospital) bearing a middle-aged woman who had developed an 
acute left-sided weakness that morning. Fearing a stroke, her family called 911. Upon ex-
amination, doctors assessed her as an 11 on the National INstitutes of Health (NIH) Stroke 
Scale, evidenced by dysarthria (slurred speech), left facial droop, and severe left arm and 
leg weakness. An X-ray computed tomography scan (CT) of her head ruled out bleeding 
in the brain. 
The patient was given IV tPa (intra-
venous clot-busting medication) less 
than an hour after symptom onset. A 
CT angiogram of the head showed a 
blood clot in the right middle cerebral 
artery. She was taken to the angio suite 
where neurointerventionalist Wayne 
Olan, M.D., assistant professor of neu-
rological surgery, and colleague Dimi-
tri Sigounas, M.D., assistant professor 
of neurological surgery, used a stent-
retriever device to successfully remove 
the clot. After the procedure she had 
only mild left facial weakness and mild 
left hand incoordination. The woman 
was recently seen in the GW Medical 
Faculty Associates clinic and has subtle 
left facial droop but is otherwise back to 
normal. She is working, performing all 
of her activities of daily living, walking 
independently, and driving.
Stroke is a killer. Thanks to new procedures and proactive stroke prevention measures, 
stroke has, in the last decade, dropped to fifth from the third leading cause of death in 
the United States. Rapid response is crucial; quick recognition and treatment can save 
lives or minimize the long-term effects of a stroke. “Time is brain” is a key mantra of stroke 
neurology. Not long before the incident described above, GW Hospital was certified as 
a Comprehensive Stroke Center, a designation which may have saved the woman’s life.
TIME IS BRAIN 
In the event of a stroke, rapid 
response is crucial; quick recog-
nition and treatment can save 
lives or minimize the long-term 
effects of a stroke. GW Hospital is 
certified as a Comprehensive Stroke 
Center, which is a designation that 
recognizes the specific capabilities 
of hospitals that can treat the most 
complex stroke cases. Less than 
2 percent of U.S. hospitals — less 
than 100 — have that certification. 
L
Turn Back Time by Acting Fast
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What is a Comprehensive Stroke Center (CSC)? The des-
ignation recognizes the specific capabilities of hospitals 
that can treat the most complex stroke cases. Less than 
2 percent of U.S. hospitals — less than 100 — have that certi-
fication. “It means that we have the clinical expertise to take 
care of complicated stroke cases,” says Christopher Leon-
Guerrero, M.D., assistant professor of neurology at the GW 
School of Medicine and Health Sciences, who attends the 
stroke and general inpatient service at GW Hospital. “In ad-
dition to providing the routine care that Primary Stroke Cen-
ters can deliver, we can provide endovascular procedures 
on a 24/7 basis, and we’re actively engaged in research tri-
als. It also means we have more vigorous metrics and mea-
sures that must be collected, so we’re constantly examining 
data and re-evaluating service to patients.”
The Joint Commission and American Heart Association/
American Stroke Association instituted a new level of cer-
tification in September 2012 to identify the medical facili-
ties with the resources, staff, and training, such as advanced 
imaging capabilities and specialized treatments, necessary 
for the care of complex stroke cases. “This designation 
demonstrates not only the 
unique expertise of our phy-
sicians, but also the exacting 
collaborative procedures that 
GW Hospital has developed 
involving everyone from the 
transport staff, technologists, 
nurses, and physicians to the 
CEO and hospital leadership,” 
says Henry Kaminski, M.D., 
chair of the Department of 
Neurology and Meta Amalia 
Neumann Professor of Neurol-
ogy at SMHS.
GW’s CSC certification is 
good news for a region that 
sits at the northern end of the 
so-called “stroke belt,” a swath 
of mostly southern states 
stretching west to Texas with 
a high incidence of stroke. “The treatments that we now 
have,” says Leon-Guerrero, “have been proven to lower the 
amount of damage people suffer from strokes.” The evolu-
tion of advances in stroke treatment can be described in 
three categories:
 > Primary stroke prevention: Preventive measures, such 
as diet, blood pressure control, and exercise, can lower 
the risk of stroke.
 > Acute treatment: IV tPA (intravenous tissue plasmino-
gen activator) clot-busting medication can be given in 
the first 4 1/2 hours to dissolve the clot and results in 
better clinical outcomes for patients.
 > Endovascular procedures: These are designed to re-
store perfusion to the brain in areas that are blocked off. 
For example, a stent-retriever or “stent-triever,” can be 
used to deploy a stent to pull the clot out of an artery. 
“We offer this to patients up to six hours from symp-
tom onset,” says Leon-Guerrero. “The clot has to be in 
a blood vessel that’s reachable by catheter, a proximal 
large vessel occlusion. Some clots are so small that they 
are not amenable to this procedure.”
“We have the clinical expertise to take care of complicated stroke cases. In addition 
to providing the routine care that Primary Stroke Centers can deliver, we can provide 
endovascular procedures on a 24/7 basis, and we’re actively engaged in research trials. 
It also means we have more vigorous metrics and measures that must be collected.”
CHRISTOPHER LEON-GUERRERO, M.D.
SPOTTING SIGNS OF STROKE
 > Sudden numbness or 
weakness of the face, 
arm, or leg, especially 
on one side of the body
 > Sudden confusion, 
trouble speaking, or 
understanding
 > Sudden trouble see-
ing or blurred vision 
in one or both eyes
 > Sudden trouble walk-
ing, dizziness, loss of 
balance or coordination
 > Sudden severe headache 
with no known cause
TAKING THE CARE FURTHER
In addition to the routine care that GW delivers as a Comprehensive 
Stroke Center, the hospital is also actively engaged in research trials. It 
is constantly examining data and re-evaluating its service to patients.
GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES    13
evaluation covers am-
bulation, transportation, 
mobility, and self-care, 
and it is scaled from total 
independence to maxi-
mum assistance needed.
Following the CSC 
certification, the unit has 
been receiving more re-
ferrals from stroke. Along with Ty Lai, M.D., instructor of 
neurology at SMHS, Sharma manages the unit and 
they determine, with the neurologist, how 
much daily therapy can be tolerated. “We 
have to be alert to changes in cogni-
tion during evaluation; whether a 
stroke might be getting bigger, or 
a new stroke is occurring,” she 
adds.
The benefits of aggressive 
therapy are substantial and rel-
atively rapid. “We can see re-
covery in three to four weeks, 
sometimes in two weeks,” she 
says. “We see patients go from 
being significantly weak on 
one side to being able to have 
fully restored function.”
Among the basic requirements 
for a CSC is to treat 20 or more pa-
tients per year with a diagnosis of sub-
arachnoid hemorrhage caused by an aneu-
rysm and to administer IV tPA 25 or more times 
per year for eligible patients with acute ischemic stroke. 
Leon-Guerrero says GW Hospital is expecting 600 to 
700 stroke patients in 2016 and welcomes the new status 
the hospital has for serving the community. “I enjoy acute 
decision-making,” he explains. “I like to deal with patients 
who are faced with these unfortunate life-changing events, 
and neurology is filled with life-changing events. There’s a 
chance you can make a huge and lasting impact on some-
one’s life.”
Leon-Guerrero says elapsed time is of the essence. “The 
earlier you treat, the more likely the patient will benefit,” 
he says. “These devices are also all time dependent.”  Dis-
agreement among practitioners remains over treating pa-
tients beyond the six hour mark. Another contentious issue 
is figuring out when to start the clock when a person wakes 
up with stroke symptoms. As of yet, no biomarkers in the 
blood have been discovered that could put a “time stamp” 
on onset.
Damage to the core of the brain is inevitable in virtually 
all strokes. The part of the brain not getting enough 
blood, but which is salvageable, is the pen-
umbra (the cells surrounding a blockage 
where blood flow and oxygen levels 
are reduced). “The sooner we can 
restore profusion, the more of the 
penumbra we can save,” Leon-
Guerrero explains.
When a person suffers a 
stroke, the treatment protocol 
shifts to secondary stroke pre-
vention, aimed at reducing the 
risk of reoccurrence. GW Hos-
pital has a 16-bed inpatient 
rehabilitation unit. “We use an 
evaluation system called the 
Functional Independent Measure, 
an ordinal scale from one to seven 
that determines the level of assistance 
the patient needs,” says Annu Sharma, 
D.O., instructor of neurology, who works 
in the rehab department at GW Hospital. The 
“This designation demonstrates not only the unique expertise of our 
physicians, but also the exacting collaborative procedures that GW Hospital 
has developed involving everyone from the transport staff, technologists, 
nurses, and physicians to the CEO and hospital leadership.”
HENRY KAMINSKI, M.D.
ACT FAST 
F ace: Facial drooping
A rm: Arm weakness
S peech: Difficulty or slurred speech
T ime: Call 911 immediately 
LIMITING THE DAMAGE 
Damage to the core of the brain is inevitable in virtu-
ally all strokes. The part of the brain not getting enough 
blood, but which is salvageable, is the penumbra. The 
sooner profusion is restored, the more of the penum-
bra can be saved. The benefits of aggressive therapy are 
substantial and relatively rapid. Recovery can be seen 
in three to four weeks, sometimes in two weeks.
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GLOBAL MENTAL HEALTH PROGRAM PROVIDES UNIQUE TRAINING OPPORTUNITIES FOR RESIDENTS
BY THOMAS KOHOUT AND SANDEEP RAVINDRAN
Addressing Global Mental Health Issues 
Across Town and Around the World
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Many of those fleeing the destruction take an arduous route out of Syria, traveling hun-
dreds of miles on foot across Turkey to the Aegean Sea. From the Turkish coast, the refu-
gees board overcrowded boats for a risky water-crossing to reach Greek islands Chios 
and Lesbos, and then it’s on to the Greek mainland and into Europe. Along the way, teams 
of nongovernmental organization (NGO) aid workers triage the incoming refugees, spot-
ting the sick from among the weary and offering what help they can. Amidst the flow of 
refugees, volunteers, global media, and border patrols during a peak in the exodus last 
November 2015 stood Catherine May, M.D., associate clinical professor of psychiatry and 
behavioral sciences at the GW School of Medicine and Health Sciences (SMHS), assess-
ing the mental health landscape on behalf of medical NGO Remote Area Medical (RAM). 
It was an emergency mission made possible by Allen Dyer, M.D., Ph.D., professor of 
psychiatry and behavioral sciences at SMHS, who leads the department’s Global Men-
tal Health residency track program. RAM was organizing a medical response mission to 
Greece, which is serving as a primary stop-over location for Syrian refugees. The group 
turned to Dyer for a recommendation based on previous associations as well as his repu-
tation as a global mental health expert. He assembled a team led by May that included 
GW resident alumni Nicole Nguyen Perras, M.D., RESD ’16, and Sandeep Denduluri, M.D., 
RESD ’14. May’s mission was organized in fairly short order, in part because the depart-
ment’s second-year residents were already engaged in a simulation exercise where they 
were preparing to respond to a yet-to-occur global disaster. 
At the height of the refugee influx, Greece was receiving as many as 6,000 refugees a 
day. They were in “migration” mode, eager to reach northern Europe, focused on physi-
cal, not emotional, needs. 
“That situation rapidly changed in March 2016, with the European Union-Turkey ac-
cord,” explains Dyer. “With refugees unable to move forward, local resources became 
strained and the humanitarian workers soon became overwhelmed.”
The United States Embassy in Athens, in conjunction with Greek NGO METAdrasi, again 
turned to Dyer and May to lead a program, “Building Resilience in Humanitarian Workers,” 
which took place in Athens in June 2016. The program also provided an opportunity for 
Fatima Noorani, M.D., RESD ’16, who participated in the workshop while still a resident. 
Specializing in Global Mental Health
The department has been involved with Global Mental Health for nearly two decades. 
Five years ago, James Griffith, M.D., chair of the Department of Psychiatry and Behav-
ioral Sciences and Leon M. Yochelson Professor of Psychiatry at SMHS, parlayed the de-
partment’s clinical expertise into the nationally recognized Global Mental Health (GMH) 
residency training program. While all of GW’s psychiatry residents participate in GMH 
training, and second-year residents participate in a variety of seminar series, typically a 
quarter of GW’s 24 residents seek more specialized training. 
As the head of the GMH program, Dyer prepares psychiatry residents to respond. Resi-
dents in the GMH track participate in up to a year’s worth of international training experi-
ences, while fourth-year residents can spend as much as eight months of their final year 
of training on international missions. During the past two years, GMH track residents par-
ticipated in projects in Bangalore, India; West Bank, Palestine; Nigeria; Cambodia; Natal, 
South Africa; and Greece. 
PRIORITIZING MENTAL HEALTH CARE
Whether health care professionals 
are working in a post-conflict setting, 
in low-income countries with limited 
resources, or with refugees and torture 
survivors in the United States, mental 
health is a crucial aspect of care. 
Often underfunded, mental health 
care is vital to a long, healthy life. 
Since 2011, according to the United Nations High Commissioner for Refugees, 
4.8 million men, women, and children have fled Syria, a nation devastated by five 
years of warfare. Nearly 7 million more are internally displaced within the country. 
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These projects serve as unique learning opportunities, 
says Griffith. “Most of the time, you’re working with a very 
high-need population that has very few resources, little 
funding, and very few mental health professionals,” he ex-
plains, “so there’s a lot of improvisation, learning how to use 
the strengths of a culture, strengths of families, to promote 
mental health.”
In the early years of the program, residents bore their 
costs of travel for international projects, while GW main-
tained continued salary 
support. Fortunately, the 
Charles and Sonia Akman 
Professorship in Global 
Psychiatry, established in 
2012, now offsets the trav-
el expenses for many of 
those international proj-
ects. Together with travel 
funds from the Depart-
ment of Psychiatry and 
Behavioral Sciences and 
the SMHS Office of Inter-
national Medicine Pro-
grams, personal expenses 
for residents on interna-
tional rotations have been 
substantially reduced.
Global Mental Health Begins at Home
Around the world, mental health is the number one prior-
ity in terms of Disease Adjusted Life Years, the measure of 
the impact of health problems. Whether health care profes-
sionals are working in a post-conflict setting, in low-income 
countries with limited resources, or with refugees and tor-
ture survivors in the United States, mental health is a cru-
cial aspect of care. “These are all different populations of 
people, but they share in common abusive circumstances 
or settings where there are very few resources for mental 
health,” says Griffith.
To that end, the department’s GMH track has become an 
important feature of the school’s residency program. “This 
is a big drawing card, and one of the reasons that residents 
come across the country to train here rather than some-
where else,” he says. In recognition of its innovative cur-
riculum, the American College of Psychiatrists awarded the 
global mental health program the 2016 Award for Creativity 
in Psychiatric Education. 
The program was a good fit for the multi-ethnic Wash-
ington, D.C. area, which, according to Griffith, is estimat-
ed to have more than 40,000 political torture-survivors in 
addition to other refugees from more than 50 countries. 
Residents in the GMH track rotate at the Northern Vir-
ginia Family Service, which provides community mental 
health services to immigrant and refugee populations. 
It’s “a perfect example of the global mental health work that 
we do locally,” says Eindra Khin Khin, M.D., RESD ’08, B.S. 
’01, assistant professor of psychiatry and behavioral sci-
ences at SMHS.
Khin Khin leads the department’s Human Rights Clinic, 
which works in close collaboration with Physicians for Hu-
man Rights to assess asylum seekers. Most individuals have 
suffered political oppression and have been tortured by 
their governments or “under color of the law” in their home 
countries. Their asylum petitions are based upon the threat 
of harm were they to return to their home countries. Oth-
ers seek asylum protection as victims of human trafficking or 
other crimes under the Victims of Trafficking and Violence 
Protection Act.
“In this day and age of globalization, you really don’t have 
to leave wherever you are to do global mental health proj-
ects,” says Khin Khin, who has worked with many immigrant 
and refugee populations, and supervises pro bono psychi-
atric evaluations for people seeking asylum status in the 
United States. 
She isn’t alone in her commitment to global mental health. 
For Michael D. Morse, M.D., RESD ’16, clinical instructor 
of psychiatry and behavioral sciences at SMHS, practicing 
medicine — specifically the diagnosis and treatment of pa-
tients with mental disorders — was always part of his plan. It 
wasn’t until he journeyed to Jerusalem between college and 
medical school, however, that he witnessed how his passion 
for psychiatry and global health could have a real impact on 
physicians and patients in the Middle East. 
“With courage, humility, and dogged persistence, Mi-
chael has opened doors in the West Bank and Gaza, and 
showed how building mental health services can further the 
cause of peace,” says Griffith.
In 2008, Morse, while still a student at the Harvard Medi-
cal School, created the Palestinian Medical Education Initia-
tive (PMED), an international NGO based in the West Bank 
and in the United States. By 2015, the group earned inter-
national recognition, receiving funding from the German 
Regional Fund for the Middle East and North Africa to in-
tegrate mental health services into primary care settings in 
Gaza and the West Bank, and for parenting classes and other 
mental health initiatives in Ramallah.
“Cross-cultural competency is an essential part of any 
residency training,” says Amir Afkhami, M.D. ’03, Ph.D., as-
sociate professor of psychiatry and behavioral sciences, and 
of global health at SMHS, highlighting a strength of GW’s 
program. “Integrating global mental health in that training is 
a great vehicle to teach that to residents.”
He adds that “there’s much to learn from the global health 
setting in terms of engaging with the community, and it’s 
more important than ever. Most places don’t have the kind 
of faculty that we have at George Washington University, 
with the kind of experience that we have, where this can be 
taught in the way we can.” 
Around the world, 
mental health is the 
number one priority 
in terms of Disease 
Adjusted Life 
Years, the measure 
of the impact of 
health problems. 
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Kohrt returned to the GW School of Medicine and Health Sciences (SMHS) to deliver the 
22nd Annual Seymour Perlin, M.D., Lecture on Suicidology. Perlin, Professor Emeritus of 
Psychiatry and Behavioral Sciences at SMHS, led the school’s psychiatry residency pro-
gram from 1977 to 1993. The Seymour Perlin, M.D., endowment fund was established 
in 1987 to honor the renowned leader and mentor 
who specialized in the field of suicidology and to 
support an annual grand rounds lecture series fo-
cusing on suicide.
In his presentation, “Suicide Prevention: Cross-
Cultural Perspectives for Refugees and Global 
Mental Health,” Kohrt addressed how people think 
about suicide from a global perspective and how 
that can inform how we better treat refugees in the 
United States.
 “The United States is the largest recipient of 
Bhutanese refugees, about 800,000 have settled 
here,” says Kohrt. “If you look at refugees in the 
United States, Bhutanese have a suicide rate of 
24.4 per 100,000. This is a higher suicide rate than 
when the Bhutanese were living in refugee camps 
in Nepal, or for Bhutanese resettled in other countries.”
Disaster, war, conflict; trauma and abuse; discrimination; stresses of acculturation and 
dislocations; and isolation and lack of social support are all important risk factors, accord-
ing to Kohrt, and part of refugees’ experiences, making them a highly vulnerable group. 
However, refugee resettlement policies in the United States often resettle refugees in 
rural areas where mental health services are difficult to access. They also separate mem-
bers of extended families that had lived together for decades in refugee camps, sending 
them to different regions of the United States where they can no longer maintain their 
connectedness.
 “The take-home message here is the concept of ethnopsychology, the idea that every 
cultural group has their own way of understanding emotions, feeling, senses, suffering,” 
he says.  There are two key pieces to this for the Bhutanese refugees. “One is the idea of 
the heart-mind, the location of emotions and memories; the other is the idea of the brain-
mind, where logic and social control and expectations are all modulated.”
PREVENTING SUICIDE IN REFUGEES
In his presentation, “Suicide Preven-
tion: Cross-Cultural Perspectives for 
Refugees and Global Mental Health,” 
Brandon Kohrt, M.D., Ph.D., RESD ’13, 
assistant professor of psychiatry, 
global health, and cultural anthrol-
ogy at Duke University, addressed 
how people think about suicide 
from a global perspective and how 
that can inform how we better treat 
refugees in the United States. 
Disaster, war, conflict; trauma and 
abuse; discrimination; stresses of 
acculturation and dislocations; and 
isolation and lack of social support are 
all important risk factors for suicide.
“How can we improve suicide prevention services for refugees in the United States, 
as well as create feasible solutions in settings within the United States where refugees 
are commonly resettled but there is almost no psychiatric care?” asked Brandon 
Kohrt, M.D., Ph.D., RESD ’13, assistant professor of psychiatry, global health, and 
cultural anthropology at the Duke Global Health Institute at Duke University.
The Refugee Mind
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